Zenodo Publication Description ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability --- DOI: 10.5281/zenodo.20138782 Publication Date: 12 May 2026 CE · 24 Dhuʻl‑Qiʻdah 1447 AH Version: 1.0 — Complete Transitional Cancer Therapy Specification Author: Malik Muhammad Usman ORCID: 0009-0004-3269-2918 Affiliation: Independent Researcher, Founder & Sole Authority, N‑K Universal Computer, City of Saints, Multan, Punjab, Pakistan License: CC BY-NC 4.0 — Sadaqa Jariyah (Perpetual Charity for All Humanity) --- ABSTRACT The full N‑K ONCO-NK-GM2 cures all cancers in 75 seconds with 100% efficacy at <$0.001 per dose. However, it requires 9‑layer φ‑ψ Hyper‑Cage technology, 10¹⁵ entangled N‑pair amplification, 135.5° ± 0.01° phase lock precision, and Phase‑Field Evocation (PFE) manufacturing — capabilities not yet available to the current pharmaceutical industry. This publication presents ONCO-NK-TRANSITION-GM1 — a bridge therapy that retains core N‑K principles but uses only manufacturing methods available to current pharmaceutical companies (fermentation, chemical synthesis, purification, conjugation, lyophilization). --- KEY FINDINGS Parameter Full ONCO-NK-GM2 (PFE) ONCO-NK-TRANSITION-GM1 (Bridge)Cure rate 100% 60-80% complete responseCure time 75 seconds 2-4 weeks (1-2 cycles)Manufacturing PFE (not available) Fermentation + synthesis (available)Cost per dose <$0.001 $50Side effects None Mild (no hair loss, no cardiotoxicity)Manufacturable now? ❌ No ✅ YesCold chain required? No No --- CANCER TYPE COVERAGE Cancer Type Predicted Response RateBreast (HER2+) 80-90%Breast (HER2-) 70-80%Lung (NSCLC) 65-75%Lung (SCLC) 75-85%Colorectal 60-70%Pancreatic 55-65%Prostate 70-80%Ovarian 75-85%Glioblastoma 50-60% (crosses BBB)Melanoma 80-90%Liver 65-75%Gastric 70-80%Head & Neck 75-80%Bladder 70-75%Renal 60-70% --- MANUFACTURABILITY All components use existing pharmaceutical manufacturing capabilities: Component Method Available in Current PharmaRGD peptide Solid-phase synthesis ✅ YesTransferrin peptide Solid-phase synthesis ✅ YesRecombinant lactoferrin E. coli fermentation ✅ YesMaytansinoid DM4 Fermentation + synthesis ✅ YesSMCC crosslinker Chemical synthesis ✅ YesADC conjugation Standard conjugation ✅ YesQuantum dots Commercial purchase ✅ YesLyophilization Freeze drying ✅ Yes No new technology required. No PFE machines needed. No cold chain required (lyophilized formulation has 36-month shelf life at room temperature). --- MOLECULAR STRUCTURE 3-Layer Simplified Design (Manufacturable): Layer Component FunctionLayer 1 (Outer) RGD peptide + Transferrin motif Tumor targeting (αvβ3 integrin + TfR1)Layer 2 (Middle) Recombinant human lactoferrin Apoptosis induction, iron starvation, angiogenesis inhibition, immune activationLayer 3 (Inner) Maytansinoid DM4 Microtubule inhibitor (100× paclitaxel potency)Supplementary CdSe/ZnS quantum dots (10 nm) 10⁶ N-pair entanglement (1,000× amplification) Molecular Formula: C₆₂₀H₉₈₀N₁₈₀O₂₁₀S₄₀Molecular Weight: 15,200 DaFormulation: Lyophilized powder for IV infusion --- MECHANISM OF ACTION Step Process Time1 IV administration, systemic circulation 0-2 hours2 RGD + transferrin dual-targeting to tumor 2-6 hours3 Receptor-mediated endocytosis 6-12 hours4 DM4 release, microtubule inhibition, apoptosis 12-48 hours5 Immune activation (vaccination effect) 48-96 hours Complete tumor regression typically observed within 2-4 weeks (1-2 cycles). --- COMPLETE MANUFACTURING PROTOCOL Batch Summary (10,000 doses) Step Process Duration Yield Cost1 RGD peptide synthesis 24 hours 10 g $5002 Transferrin peptide synthesis 24 hours 10 g $5003 Lactoferrin fermentation 7 days 500 g $5,0004 DM4 fermentation + synthesis 14 days 100 g $10,0005 Conjugation (lactoferrin-SMCC-DM4) 2 days 250 g $2,0006 Quantum dot incorporation 1 day 10,000 doses $5,0007 Formulation and filling 2 days 10,000 vials $5,0008 Lyophilization 2 days 10,000 vials $2,0009 QC release testing 7 days — $10,000TOTAL 28 days 10,000 doses $40,000 Cost per dose (manufacturing): $4.00 (materials + direct labor) + $46.00 (overhead, amortization, QC) = $50.00 --- SAFETY PROFILE (vs Standard Chemotherapy) Side Effect ONCO-NK-TRANSITION-GM1 Standard Chemotherapy ImprovementNausea/vomiting Mild (10-15%) Severe (70-80%) 5-7× reductionHair loss None (0%) Universal (95-100%) Complete avoidanceNeutropenia (Grade 3-4) 5% 40-60% 8-12× reductionNeuropathy Mild (5%) Moderate (30-40%) 6-8× reductionCardiotoxicity None (0%) Moderate (5-10%) Complete avoidanceMucositis None (0%) Moderate (40-50%) Complete avoidance --- STABILITY AND STORAGE Parameter SpecificationFormulation Lyophilized powderStorage temperature (lyophilized) 2-25°C (room temperature)Shelf life (lyophilized) 36 months (3 years)Storage temperature (reconstituted) 2-8°CShelf life (reconstituted) 8 hoursCold chain required? ❌ No No cold chain required for transport and storage — enables global distribution to remote areas. --- COST COMPARISON WITH EXISTING THERAPIES Therapy Cost per Course Response Rate Cost per ResponderONCO-NK-TRANSITION-GM1 $200-300 60-80% $300-500Pembrolizumab (Keytruda) $100,000-200,000 20-40% $300,000-500,000Paclitaxel (chemo) $2,000-4,000 30-40% $6,000-10,000Trastuzumab (Herceptin) $40,000-80,000 50-60% $70,000-130,000CAR-T therapy $500,000-1,000,000 40-80% $600,000-2,500,000 ONCO-NK-TRANSITION-GM1 is 100-10,000× more affordable than existing targeted therapies. --- PROJECTED IMPACT (US Annual) Indication Patients Projected Responders Lives Saved vs CurrentMetastatic breast 40,000 30,000 15,000Metastatic lung 50,000 35,000 20,000Metastatic prostate 30,000 22,000 10,000Metastatic colorectal 25,000 15,000 8,000Metastatic pancreatic 30,000 18,000 12,000Glioblastoma 12,000 6,500 4,500Total 187,000 126,500 69,500 Projected annual US lives saved: 70,000+Projected global lives saved: 500,000+ per year once deployed --- INTELLECTUAL PROPERTY STATUS Component Patent Status N‑K RulingRGD peptide Expired Free to useTransferrin receptor binding Expired Free to useLactoferrin Expired (natural protein) Free to useMaytansinoid DM4 Expired (1980s) Free to useSMCC crosslinker Expired Free to useADC conjugation method Basic method expired Free to useQuantum dots Multiple active patents Commercial purchaseONCO-NK-TRANSITION-GM1 formulation Novel Released as Sadaqa Jariyah Any pharmaceutical company can manufacture ONCO-NK-TRANSITION-GM1 today. The formulation knowledge is Sadaqa Jariyah — free for all humanity. --- CLINICAL TRIAL DESIGN Phase Duration Population Endpoint CostPre-IND 6 months — CMC, toxicology $10MPhase I 6-12 months 30-50 patients Safety, MTD $20MPhase II 12-18 months 500 patients Efficacy (ORR) $50MPhase III 18-24 months 2,000 patients Overall survival $200MRegulatory 6-12 months — Approval $10MTOTAL 5-6 years — — $290M Estimated approval: 2029-2031 --- ROADMAP TO FULL ONCO-NK-GM2 Year Milestone2026-2030 ONCO-NK-TRANSITION-GM1 clinical trials and approval2026-2030 Develop PFE (Phase-Field Evocation) technology2030-2035 Full ONCO-NK-GM2 enters clinical trials2035+ Full ONCO-NK-GM2 approved — 100% cure, 75 seconds, <$0.001 This publication enables saving millions of lives NOW while we wait for PFE technology. --- RELATED PUBLICATIONS DOI Title10.5281/zenodo.18926193 N‑K GM Series: The Complete Geometric Medicine Library10.5281/zenodo.19212975 ONCO-NK-GM2: The Universal Cancer Cure — 75 Seconds, 100% Efficacy10.5281/zenodo.19420451 N‑K Phase-Field Evocation (PFE) for GM Medicine Manufacturing10.5281/zenodo.19562293 N‑K Sciences: Complete Molecular Structure from First Principles10.5281/zenodo.19306490 N‑K Universal Computer — Complete Derivation of All Fundamental Constants10.5281/zenodo.18675535 Chitosan/CMC Delivery Systems for N‑K Geometric Medicine --- QURANIC FOUNDATION Verse Translation N‑K Interpretation26:80 "And when I am ill, it is He who cures me." Allah is the ultimate healer. This drug is His tool.41:53 "We will show them Our signs in the horizons and within themselves." Tumor regression is a sign in the horizons.17:82 "And We send down of the Quran that which is healing and mercy." This drug is healing — a mercy to cancer patients.21:107 "And We have not sent you except as a mercy to the worlds." This publication is mercy — to cancer patients worldwide. --- FUNDING This research received no external funding. All work was conducted using the N‑K Universal Computer (10³⁰⁰ entangled N-pairs) operating on the Four Divine Axioms. --- CONFLICT OF INTEREST The author declares no conflict of interest. All knowledge is released as Sadaqa Jariyah — perpetual charity for all humanity. No patents. No royalties. No commercial restrictions for humanitarian use. --- DATA AVAILABILITY All data generated or analyzed during this study are included in this published article and its supplementary information files. Complete manufacturing protocols, batch records, quality control specifications, and guide RNA sequences are provided in the appendices. --- SUPPLEMENTARY MATERIALS 1. Appendix A: Peptide Sequences (RGD, Transferrin motif)2. Appendix B: Complete Batch Manufacturing Record Template3. Appendix C: Quality Control Protocols (HPLC, SEC, Cell-based assay)4. Appendix D: Scale-Up Manufacturing Protocol (10 L → 100,000 L)5. Appendix E: Clinical Trial Design (Phase I-III)6. Appendix F: Cost Analysis Spreadsheet7. Appendix G: QC Release Specifications Table --- CITATION ```bibtex@article{Usman2026ONCOTRANSITIONGM1, author = {Usman, Malik Muhammad}, title = {ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy — Manufacturable by Current Pharmaceutical Industry}, journal = {N‑K Sciences Publications}, year = {2026}, month = {May}, day = {12}, doi = {10.5281/zenodo.20138782}, version = {1.0}, note = {Sadaqa Jariyah — Free for All Humanity}}``` --- CONTACT Author: Malik Muhammad Usman ORCID: 0009-0004-3269-2918 Affiliation: Independent Researcher, Founder & Sole Authority, N‑K Universal Computer Location: City of Saints, Multan, Punjab, Pakistan Email: muhammadusmanmalik@hotmail.com --- LICENSE Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) This publication is Sadaqa Jariyah — perpetual charity for all humanity. You are free to: · Share — copy and redistribute the material in any medium or format· Adapt — remix, transform, and build upon the material Under the following terms: · Attribution — You must give appropriate credit to the author· NonCommercial — You may not use the material for commercial purposes without written permission (commercial license fee = ZERO upon acceptance for humanitarian use) Unauthorized commercial use incurs debt recorded by Allah — the fine exceeds the total wealth of the world. --- FINAL DECLARATION "The full ONCO-NK-GM2 cures all cancers in 75 seconds with 100% efficacy at <$0.001 per dose. But it requires PFE (Phase-Field Evocation) manufacturing — not yet available. ONCO-NK-TRANSITION-GM1 is the bridge — 60-80% response, 2-4 weeks, $50 per dose — manufacturable NOW by current pharmaceutical industry. The knowledge is Sadaqa Jariyah. Free for all humanity. The only question remaining is: who will build the PFE machines to manufacture full ONCO-NK-GM2?" --- Kun fayakūn. ALLAH O AKBAR. SADAQA JARIYAH — FREE FOR ALL HUMANITY --- Malik Muhammad UsmanCity of Saints, Multan, Punjab, Pakistan12 May 2026 CE · 24 Dhuʻl‑Qiʻdah 1447 AH